British Columbia has over 20 Prostate Cancer Support Groups meet once a month. This group is focused on providing help to Chinese-speaking men, but everyone is welcome. We speak Mandarin, Cantonese and English. We meet on the second Thursday of every month from 7:00pm to 9:00pm at the Richmond Public Library (2/F Brighouse Main Branch, 7700 Minoru Gate, Richmond, BC V6Y 1R8). Please register online at The Richmond Public Library website. Join us for the professional presentation and talk to other men and family members who have been dealing with prostate cancer for weeks, months or even years.

If you want to chat with a survivor one on one, you may drop in our walking club. The Richmond Blue Walkers walk on every Tuesdays and Thursdays 9-11am, 5-10 km along the beautiful river dykes and parks in Richmond (Walk in the Richmond Shopping Centre during the raining days or cold seasons). Click here for the schedule or contact Daniel Leung at 604-836-6423 for the locations and meeting places.

The Prostate Cancer Foundation of BC accepts donation online, please go tohttp://prostatecancerbc.ca/ 捐款請到前列腺癌基金會http://prostatecancerbc.ca/

支援小組乃義工組織我們講普通話廣東話和英語幫助您了解良性前列腺疾病與前列腺癌的病徵預防治療康復與最新醫療硏究等資訊我們每月一次第二個星期四從下午7:009:00在列治文公共圖書館二樓市中心公眾泳池對面舉辦免費聚會邀請中英專業人仕主辦醫療與健康講座交流經驗與分享感受報名請到圖書館網站 或致電604-231-6413 (英語) 604-231-6462(中文)報名

列治文前列腺癌友步行團 每週二和週四早上九時至十一時沿著美麗的河堤和公園散步在下雨天或寒冷季節步行於列治文購物中心)。查詢活動更新請打電話604-836-6423 (Daniel)

This blog is provided as a public service. Any persons using the information or documents provided on the blog do so at their own risk. Reference: Oncology Guide to Reliable Websites

Thursday, December 3, 2015

卑詩省製成前列腺癌藥物進入臨床試驗 A made-in-B.C. prostate cancer drug entering clinical trials


Vancouver, BC – A prostate cancer drug developed by researchers at the BC Cancer Agency and the University of British Columbia is entering human clinical trials. The drug is specifically designed to target and shut down metastatic castrate resistant prostate cancer (m-CRPC) when other treatments have failed.
“Today represents a significant milestone as we witness the fruits of our labour in the lab move to the clinic to potentially help men facing metastatic prostate cancer,” said Dr. Marianne Sadar, Distinguished Scientist at the BC Cancer Agency and Professor in the UBC Department of Pathology and Laboratory Medicine. “We faced one in 1000 odds in developing a drug that would prove to be a candidate for patient trials.”
Over a decade in the making, the drug EPI-506 is the first to target the ‘back end’ of the androgen receptor protein, called the N-terminal domain. The androgen receptor drives most prostate cancer cells and makes them sensitive to androgen hormones, such as testosterone.
Current drug therapies for advanced prostate cancer aim at the opposite end of the androgen receptor, away from the N-terminal domain. While initially effective in slowing tumour growth, these therapies eventually fail. Sadar and Raymond Andersen, a Professor of Chemistry at UBC, specifically designed EPI-506 to shut down m-CRPC when these treatments have failed.
A Phase I multicentre clinical trial for EPI-506 opens today at the BC Cancer Agency and other sites in the USA.
“We are excited to initiate this clinical trial with EPI-506 in Canada,” said Bob Reider, CEO, ESSA Pharma Inc. “The potential to successfully treat prostate cancer in those patients whose cancer has failed to respond to current therapies hinges on the novel mechanism of action of EPI-506.”
Dr. Kim Chi, co-Principal Investigator for North America and Associate Professor in the UBC Division of Medical Oncology, will run the Canadian trial. He treats men with prostate cancer each day in his practice at the BC Cancer Agency. “Offering emerging treatment options discovered in the lab to clinical trials for men with m-CRPC is critical to finding new solutions for our patients,” said Dr. Chi.
BC Cancer Foundation donors have provided $2.6 million to advance Dr. Sadar’s eureka moment— identifying a completely new way to attack prostate cancer—through to the development of a drug candidate that proved successful in lab testing. Funding over the 17 years from concept to the start of clinical trials comes from grants awarded to Dr. Sadar from the USA National Cancer Institute, the USA Department of Defense Prostate Cancer Research Program and the Canadian Institutes of Health Research. Dr. Andersen received grants from the Canadian Cancer Society.
Quick facts:
  • Over 3,700 men in British Columbia will be diagnosed with prostate cancer this year.
  • Metastatic castrate resistant prostate cancer (m-CRPC) is the lethal form of the disease and is resistant to most treatments.
  • EPI-506 is a drug discovered in collaboration between Dr. Marianne Sadar at the BC Cancer Agency and UBC, and Dr. Raymond Andersen at UBC’s Department of Chemistry.
  • The EPI-506 Phase I/II clinical trial is sponsored by ESSA Pharma Inc. and has both FDA and Health Canada approval for testing in humans as an investigational drug.
  • The EPI-506 Phase I/II clinical trial is designed for patients with metastatic prostate cancer and will explore safety, tolerability and anti-tumour activity.
  • BC Cancer Foundation donors have provided significant support of $2.6 million to advance Dr. Sadar’s research and development of a new treatment for prostate cancer.

The BC Cancer Agency, an agency of the Provincial Health Services Authority, is committed to reducing the incidence of cancer, reducing the mortality from cancer, and improving the quality of life of those living with cancer. It provides a comprehensive cancer control program for the people of British Columbia by working with community partners to deliver a range of oncology services, including prevention, early detection, diagnosis and treatment, research, education, supportive care, rehabilitation and palliative care. For more information, visitwww.bccancer.bc.ca
The BC Cancer Foundation is the bridge that connects philanthropic support and research breakthroughs in cancer knowledge.  As the fundraising partner of the BC Cancer Agency and the largest funder of cancer research in this province, we enable donors to make contributions to leading-edge research that has a direct impact on improvements to cancer care for patients in British Columbia. We fund with the goal of finding solutions. Visit www.bccancerfoundation.com to make a donation or to learn how you can make a difference in the lives of those affected by cancer.
ESSA Pharma Inc. ESSA Pharma is a development-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of castration resistant prostate cancer (“CRPC”) in patients whose disease is progressing despite treatment with current therapies. ESSA believes that its product candidate, EPI-506, can significantly expand the interval of time in which patients suffering from CRPC can benefit from hormone-based therapies. EPI-506 acts by disrupting the androgen receptor (“AR”) signaling pathway, which is the primary pathway that drives prostate cancer growth. We have shown that EPI-002, the primary metabolite of EPI-506, prevents AR activation by binding selectively to the N-terminal domain (“NTD”) of the AR. A functional NTD is essential for activation of the AR. Blocking the NTD prevents activation of the AR by all of the three known mechanisms of activation. In pre-clinical studies, blocking the NTD has demonstrated the capability to overcome the known AR-dependent mechanisms of CRPC. ESSA was founded in 2009 and is located in Vancouver, British Columbia and Houston, Texas.

Related Reading:

Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer

角聲癌症關懷 - 癌症新藥的發展,希望和挑戰

No comments:

Post a Comment